1
|
Shahrokny P, Maison N, Riemann L, Ehrmann M, DeLuca D, Schuchardt S, Thiele D, Weckmann M, Dittrich AM, Schaub B, Brinkmann F, Hansen G, Kopp MV, von Mutius E, Rabe KF, Bahmer T, Hohlfeld JM, Grychtol R, Holz O. Increased breath naphthalene in children with asthma and wheeze of the All Age Asthma Cohort (ALLIANCE). J Breath Res 2023; 18:016003. [PMID: 37604132 DOI: 10.1088/1752-7163/acf23e] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2023] [Accepted: 08/21/2023] [Indexed: 08/23/2023]
Abstract
Exhaled breath contains numerous volatile organic compounds (VOCs) known to be related to lung disease like asthma. Its collection is non-invasive, simple to perform and therefore an attractive method for the use even in young children. We analysed breath in children of the multicenter All Age Asthma Cohort (ALLIANCE) to evaluate if 'breathomics' have the potential to phenotype patients with asthma and wheeze, and to identify extrinsic risk factors for underlying disease mechanisms. A breath sample was collected from 142 children (asthma: 51, pre-school wheezers: 55, healthy controls: 36) and analysed using gas chromatography-mass spectrometry (GC/MS). Children were diagnosed according to Global Initiative for Asthma guidelines and comprehensively examined each year over up to seven years. Forty children repeated the breath collection after 24 or 48 months. Most breath VOCs differing between groups reflect the exposome of the children. We observed lower levels of lifestyle-related VOCs and higher levels of the environmental pollutants, especially naphthalene, in children with asthma or wheeze. Naphthalene was also higher in symptomatic patients and in wheezers with recent inhaled corticosteroid use. No relationships with lung function or TH2 inflammation were detected. Increased levels of naphthalene in asthmatics and wheezers and the relationship to disease severity could indicate a role of environmental or indoor air pollution for the development or progress of asthma. Breath VOCs might help to elucidate the role of the exposome for the development of asthma. The study was registered at ClinicalTrials.gov (NCT02496468).
Collapse
Affiliation(s)
- P Shahrokny
- Fraunhofer ITEM, Department of Clinical Airway Research, German Center for Lung Research (BREATH, DZL), Hannover, Germany
| | - N Maison
- Department of Pediatrics, Dr. von Hauner Children's Hospital, LMU University Hospital, LMU Munich, Germany German Center for Lung Research (CPC-M, DZL), Munich, Germany
- Institute of Asthma and Allergy Prevention, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany
| | - L Riemann
- Department of Paediatric Pneumology, Allergology and Neonatology, Hannover Medical School, German Center for Lung Research (BREATH, DZL), Hannover, Germany
- Clinician Scientist Program TITUS, Else-Kröner-Fresenius-Stiftung, Hannover Medical School, Hannover, Germany
- Institute of Immunology, Hannover Medical School, Hannover, Germany
| | - M Ehrmann
- Department of Pediatrics, Dr. von Hauner Children's Hospital, LMU University Hospital, LMU Munich, Germany German Center for Lung Research (CPC-M, DZL), Munich, Germany
| | - D DeLuca
- German Center for Lung Research (BREATH, DZL), Hannover, Germany
| | - S Schuchardt
- Fraunhofer ITEM, Bio- and Environmental Analytics, Hannover, Germany
| | - D Thiele
- Division of Pediatric Pulmonology and Allergology, University Children's Hospital, German Center for Lung Research (ARCN, DZL), Luebeck, Germany
- Institute of Medical Biometry and Statistics (IMBS), University Medical Center Schleswig-Holstein, Luebeck, Germany
| | - M Weckmann
- Division of Pediatric Pulmonology and Allergology, University Children's Hospital, German Center for Lung Research (ARCN, DZL), Luebeck, Germany
- Epigenetics of Chronic Lung Disease, Priority Research Area Chronic Lung Diseases, Leibniz Lung Research Center Borstel, Borstel, Germany
| | - A M Dittrich
- Department of Paediatric Pneumology, Allergology and Neonatology, Hannover Medical School, German Center for Lung Research (BREATH, DZL), Hannover, Germany
| | - B Schaub
- Department of Pediatrics, Dr. von Hauner Children's Hospital, LMU University Hospital, LMU Munich, Germany German Center for Lung Research (CPC-M, DZL), Munich, Germany
| | - F Brinkmann
- Division of Pediatric Pulmonology and Allergology, University Children's Hospital, German Center for Lung Research (ARCN, DZL), Luebeck, Germany
| | - G Hansen
- Department of Paediatric Pneumology, Allergology and Neonatology, Hannover Medical School, German Center for Lung Research (BREATH, DZL), Hannover, Germany
| | - M V Kopp
- Division of Pediatric Pulmonology and Allergology, University Children's Hospital, German Center for Lung Research (ARCN, DZL), Luebeck, Germany
- Department of Paediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
| | - E von Mutius
- Department of Pediatrics, Dr. von Hauner Children's Hospital, LMU University Hospital, LMU Munich, Germany German Center for Lung Research (CPC-M, DZL), Munich, Germany
- Institute of Asthma and Allergy Prevention, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany
| | - K F Rabe
- LungenClinic Grosshansdorf and Department of Medicine, Christian-Albrechts-University Kiel, German Center for Lung Research (ARCN, DZL), Grosshansdorf, Germany
| | - T Bahmer
- LungenClinic Grosshansdorf and Department of Medicine, Christian-Albrechts-University Kiel, German Center for Lung Research (ARCN, DZL), Grosshansdorf, Germany
- Internal Medicine Department I, University Hospital Schleswig-Holstein, UKSH - Campus Kiel, German Center for Lung Research (ARCN, DZL), Kiel, Germany
| | - J M Hohlfeld
- Fraunhofer ITEM, Department of Clinical Airway Research, German Center for Lung Research (BREATH, DZL), Hannover, Germany
- Department of Respiratory Medicine, Hannover Medical School (MHH), Hannover, Germany
| | - R Grychtol
- Department of Paediatric Pneumology, Allergology and Neonatology, Hannover Medical School, German Center for Lung Research (BREATH, DZL), Hannover, Germany
| | - O Holz
- Fraunhofer ITEM, Department of Clinical Airway Research, German Center for Lung Research (BREATH, DZL), Hannover, Germany
| |
Collapse
|
2
|
Maison N, Omony J, Illi S, Thiele D, Skevaki C, Dittrich AM, Bahmer T, Rabe KF, Weckmann M, Happle C, Schaub B, Meyer M, Foth S, Rietschel E, Renz H, Kopp MV, Hansen G, von Mutius E, Grychtol R. T2-high asthma across all ages – comparative analysis in
children and adults from the ALLIANCE cohort. Klinische Pädiatrie 2022. [DOI: 10.1055/s-0042-1754451] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- N Maison
- Dr von Hauner Children's Hospital, Ludwig Maximilians
University, Asthma and Allergy, Munich, Germany
- Helmholtz Zentrum Munich, Institute for Asthma- and Allergy Prevention
(IAP), Munich, Germany
- Comprehensive Pneumology Center – Munich (CPC-M); Member of
German Center for Lung Research (DZL), Munich, Germany
| | - J Omony
- Helmholtz Zentrum Munich, Institute for Asthma- and Allergy Prevention
(IAP), Munich, Germany
- Comprehensive Pneumology Center – Munich (CPC-M); Member of
German Center for Lung Research (DZL), Munich, Germany
| | - S Illi
- Helmholtz Zentrum Munich, Institute for Asthma- and Allergy Prevention
(IAP), Munich, Germany
- Comprehensive Pneumology Center – Munich (CPC-M); Member of
German Center for Lung Research (DZL), Munich, Germany
| | - D Thiele
- University Medical Center Schleswig-Holstein, Institute of Medical
Biometry and Statistics (IMBS), Luebeck, Germany
- Airway Research Center North (ARCN), Member of the German Center for
Lung Research (DZL), Luebeck, Germany
| | - C Skevaki
- Institute of Laboratory Medicine and Pathobiochemistry,
Philipps-University Marburg, Molecular Diagnostics, Marburg,
Germany
- Universities of Giessen and Marburg Lung Center (UGMLC), Philipps
University Marburg, German Center for Lung Research (DZL), Marburg,
Germany
| | - A-M Dittrich
- Hannover Medical School, Department of Paediatric Pneumology,
Allergology and Neonatology, Hannover, Germany
- Biomedical Research in Endstage and Obstructive Lung Disease (BREATH);
Member of the German Center for Lung Research (DZL), Hannover,
Germany
| | - T Bahmer
- LungenClinic Grosshansdorf GmbH, Grosshansdorf, Germany
- Airway Research Center North (ARCN), Member of the German Center for
Lung Research (DZL), Grosshansdorf, Germany
- University Hospital Schleswig-Holstein, Campus Kiel, Internal Medicine
Department I, Pneumology, Kiel, Germany
| | - KF Rabe
- LungenClinic Grosshansdorf GmbH, Grosshansdorf, Germany
- Airway Research Center North (ARCN), Member of the German Center for
Lung Research (DZL), Grosshansdorf, Germany
| | - M Weckmann
- University Medical Center Schleswig-Holstein, Division of Paediatric
Pneumology and Allergology, Luebeck, Germany
- Airway Research Center North (ARCN), Member of the German Center for
Lung Research (DZL), Luebeck, Germany
| | - C Happle
- Hannover Medical School, Department of Paediatric Pneumology,
Allergology and Neonatology, Hannover, Germany
- Biomedical Research in Endstage and Obstructive Lung Disease (BREATH);
Member of the German Center for Lung Research (DZL), Hannover,
Germany
| | - B Schaub
- Dr von Hauner Children's Hospital, Ludwig Maximilians
University, Asthma and Allergy, Munich, Germany
- Comprehensive Pneumology Center – Munich (CPC-M); Member of
German Center for Lung Research (DZL), Munich, Germany
| | - M Meyer
- University Children's Hospital, University of Cologne, Cologne,
Germany
| | - S Foth
- University Children’s Hospital Marburg, University of Marburg,
Marburg, Germany
- Universities of Giessen and Marburg Lung Center (UGMLC), Philipps
University Marburg, German Center for Lung Research (DZL), Marburg,
Germany
| | - E Rietschel
- University Children's Hospital, University of Cologne, Cologne,
Germany
| | - H Renz
- Institute of Laboratory Medicine and Pathobiochemistry,
Philipps-University Marburg, Molecular Diagnostics, Marburg,
Germany
- Universities of Giessen and Marburg Lung Center (UGMLC), Philipps
University Marburg, German Center for Lung Research (DZL), Marburg,
Germany
| | - MV Kopp
- University Children's Hospital, University of Bern, Department
of Paediatric Respiratory Medicine, Bern, Switzerland
- Airway Research Center North (ARCN), Member of the German Center for
Lung Research (DZL), Luebeck, Germany
- University Medical Center Schleswig-Holstein, Division of Paediatric
Pneumology and Allergology, Luebeck, Germany
| | - G Hansen
- Hannover Medical School, Department of Paediatric Pneumology,
Allergology and Neonatology, Hannover, Germany
- Biomedical Research in Endstage and Obstructive Lung Disease (BREATH);
Member of the German Center for Lung Research (DZL), Hannover,
Germany
| | - E von Mutius
- Dr von Hauner Children's Hospital, Ludwig Maximilians
University, Asthma and Allergy, Munich, Germany
- Helmholtz Zentrum Munich, Institute for Asthma- and Allergy Prevention
(IAP), Munich, Germany
- Comprehensive Pneumology Center – Munich (CPC-M); Member of
German Center for Lung Research (DZL), Munich, Germany
| | - R Grychtol
- Hannover Medical School, Department of Paediatric Pneumology,
Allergology and Neonatology, Hannover, Germany
- Biomedical Research in Endstage and Obstructive Lung Disease (BREATH);
Member of the German Center for Lung Research (DZL), Hannover,
Germany
| |
Collapse
|
3
|
Nemani SSP, Lunding L, Wegmann M, Kopp MV, Weckmann M. COL4A3 degradation may depend on MMP9 in experimental asthma
exacerbations. Klinische Pädiatrie 2022. [DOI: 10.1055/s-0042-1754465] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- SSP Nemani
- University Clinic Schleswig-Holstein, Division of Paediatric Pneumology
& Allergology, Lübeck, Germany
| | - L Lunding
- Leibniz-Center for Medicine and Biosciences Borstel, Lung Immunology,
Borstel, Germany
| | - M Wegmann
- Leibniz-Center for Medicine and Biosciences Borstel, Lung Immunology,
Borstel, Germany
| | - MV Kopp
- University of Bern, Department of Paediatric Respiratory Medicine,
Bern, Switzerland
| | - M Weckmann
- University clinic Schleswig-Holstein, Division of Paediatric Pneumology
& Allergology, Lübeck, Germany
| |
Collapse
|
4
|
Buchholz S, Künstner A, Bahmer T, Hansen G, von Mutius E, Rabe KF, Dittrich AM, Schaub B, Happle C, Kopp MV, Busch H, Weckmann M. Der Einfluss nasaler Methylierungsmuster auf den
Asthma-Phänotyp – Eine Clusteranalyse mittels Uniform Manifold
Approximation and Projection (UMAP). Klinische Pädiatrie 2022. [DOI: 10.1055/s-0042-1754463] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- S Buchholz
- Klinik für Kinder- & Jugendmedizin,
Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Sektion
für Pädiatrische Pneumologie und Allergologie, Lübeck,
Germany
- Leibniz Lungenzentrum Borstel, Programmbereich Chronische
Lungenerkrankungen; Epigenetik chronischer Lungenerkrankungen, Borstel,
Germany
- Airway Research Center North (ARCN), Mitglied des Deutschen Zentrums
für Lungenforschung (DZL), Lübeck, Germany
| | - A Künstner
- Universität zu Lübeck, Lübecker Institut
für Experimentelle Dermatologie, Systembiologie, Lübeck,
Germany
| | - T Bahmer
- LungenClinic Grosshansdorf, Abteilung Pneumologie, Grosshansdorf,
Germany
- Universitätsklinikum Schleswig-Holstein, Campus Kiel, Klinik
für Innere Medizin I, Kiel, Germany
- Airway Research Center North (ARCN), Mitglied des Deutschen Zentrums
für Lungenforschung (DZL), Grosshandsdorf, Germany
| | - G Hansen
- Medizinische Hochschule Hannover, Klinik für
Pädiatrische Pneumologie, Allergologie & Neonatologie, Hannover,
Germany
- Biomedical Research in Endstage and Obstructive Lung Disease Hannover
(BREATH), Mitglied des Deutschen Zentrums für Lungenforschung (DZL),
Hannover, Germany
| | - E von Mutius
- Ludwig-Maximilians-Universität, Haunersches Kinderspital,
Haunersches Kinderspital, München, Germany
- Comprehensive Pneumology Center (CPC-M), Mitglied des Deutschen
Zentrums für Lungenforschung (DZL), München,
Germany
| | - KF Rabe
- LungenClinic Grosshansdorf, Abteilung Pneumologie, Grosshansdorf,
Germany
- Airway Research Center North (ARCN), Mitglied des Deutschen Zentrums
für Lungenforschung (DZL), Grosshandsdorf, Germany
| | - A-M Dittrich
- Medizinische Hochschule Hannover, Klinik für
Pädiatrische Pneumologie, Allergologie & Neonatologie, Hannover,
Germany
- Biomedical Research in Endstage and Obstructive Lung Disease Hannover
(BREATH), Mitglied des Deutschen Zentrums für Lungenforschung (DZL),
Hannover, Germany
| | - B Schaub
- Ludwig-Maximilians-Universität, Haunersches Kinderspital,
Haunersches Kinderspital, München, Germany
- Comprehensive Pneumology Center (CPC-M), Mitglied des Deutschen
Zentrums für Lungenforschung (DZL), München,
Germany
| | - C Happle
- Medizinische Hochschule Hannover, Klinik für
Pädiatrische Pneumologie, Allergologie & Neonatologie, Hannover,
Germany
- Biomedical Research in Endstage and Obstructive Lung Disease Hannover
(BREATH), Mitglied des Deutschen Zentrums für Lungenforschung (DZL),
Hannover, Germany
| | - MV Kopp
- Inselspital, Universitätsklinik für Kinderheilkunde,
Bern, Switzerland
| | - H Busch
- Universität zu Lübeck, Lübecker Institut
für Experimentelle Dermatologie, Systembiologie, Lübeck,
Germany
| | - M Weckmann
- Klinik für Kinder- & Jugendmedizin,
Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Sektion
für Pädiatrische Pneumologie und Allergologie, Lübeck,
Germany
- Leibniz Lungenzentrum Borstel, Programmbereich Chronische
Lungenerkrankungen; Epigenetik chronischer Lungenerkrankungen, Borstel,
Germany
- Airway Research Center North (ARCN), Mitglied des Deutschen Zentrums
für Lungenforschung (DZL), Lübeck, Germany
| |
Collapse
|
5
|
Weckmann M, Thiele D, Liboschik L, Bahmer T, Pech M, Dittrich AM, Fuchs O, Happle C, Schaub B, Ricklefs I, Rabe KF, von Mutius E, Hansen G, König IR, Kopp MV. Cytokine levels in children and adults with wheezing and asthma show specific patterns of variability over time. Clin Exp Immunol 2020; 204:152-164. [PMID: 33202033 DOI: 10.1111/cei.13550] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2020] [Revised: 10/23/2020] [Accepted: 10/26/2020] [Indexed: 11/30/2022] Open
Abstract
Levels of cytokines are used for in-depth characterization of patients with asthma; however, the variability over time might be a critical confounder. To analyze the course of serum cytokines in children, adolescents and adults with asthma and in healthy controls and to propose statistical methods to control for seasonal effects. Of 532 screened subjects, 514 (91·5%) were included in the All Age Asthma Cohort (ALLIANCE). The cohort included 279 children with either recurrent wheezing bronchitis (more than two episodes) or doctor-diagnosed asthma, 75 healthy controls, 150 adult asthmatics and 31 adult healthy controls. Blood samples were collected and 25 μl serum was used for analysis with the Bio-Plex Pr human cytokine 27-Plex assay. Mean age, body mass index and gender in the three groups of wheezers, asthmatic children and adult asthmatics were comparable to healthy controls. Wheezers (34·5%), asthmatic children (78·7%) and adult asthmatics (62·8%) were significantly more often sensitized compared to controls (4·5, 22 and 22·6%, respectively). Considering the entire cohort, interleukin (IL)-1ra, IL-4, IL-9, IL-17, macrophage inflammatory protein (MIP)-1- α and tumor necrosis factor (TNF)- α showed seasonal variability, whereas IL-1β, IL-7, IL-8, IL-13, eotaxin, granulocyte colony-stimulating factor (G-CSF), interferon gamma-induced protein (IP)-10, MIP-1 β and platelet-derived growth factor (PDGF)-BB did not. Significant differences between wheezers/asthmatics and healthy controls were observed for IL-17 and PDGF-BB, which remained stable after adjustment for the seasonality of IL-17. Seasonality has a significant impact on serum cytokine levels in patients with asthma. Because endotyping has achieved clinical importance to guide individualized patient-tailored therapy, it is important to account for seasonal effects.
Collapse
Affiliation(s)
- M Weckmann
- Department of Pediatric Pneumology and Allergology, University Medical Center Schleswig-Holstein, Lübeck, Germany.,Member of the German Center of Lung Research (DZL), Airway Research Center North (ARCN), Lübeck, Germany
| | - D Thiele
- Member of the German Center of Lung Research (DZL), Airway Research Center North (ARCN), Lübeck, Germany.,Institut für Medizinische Biometrie und Statistik, Universität zu Lübeck, Lübeck, Germany
| | - L Liboschik
- Department of Pediatric Pneumology and Allergology, University Medical Center Schleswig-Holstein, Lübeck, Germany.,Member of the German Center of Lung Research (DZL), Airway Research Center North (ARCN), Lübeck, Germany
| | - T Bahmer
- Member of the German Center of Lung Research (DZL), Airway Research Center North (ARCN), Lübeck, Germany.,Departement for Internal Medicine I, Pneumology, University Medical Center Schleswig-Holstein, Kiel, Germany.,Department of Pneumology, Lungen Clinic Grosshansdorf, Großhansdorf, Germany
| | - M Pech
- Department of Pediatric Pneumology and Allergology, University Medical Center Schleswig-Holstein, Lübeck, Germany.,Member of the German Center of Lung Research (DZL), Airway Research Center North (ARCN), Lübeck, Germany
| | - A-M Dittrich
- Department of Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany.,Member of the German Center of Lung Research (DZL), Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), Lübeck, Germany
| | - O Fuchs
- Department of Pediatric Pneumology and Allergology, University Medical Center Schleswig-Holstein, Lübeck, Germany.,Member of the German Center of Lung Research (DZL), Airway Research Center North (ARCN), Lübeck, Germany.,Division of Respiratory Medicine, Department of Pediatrics, Inselspital, University of Bern, Bern, Switzerland
| | - C Happle
- Department of Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany.,Member of the German Center of Lung Research (DZL), Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), Lübeck, Germany
| | - B Schaub
- Department of Pediatrics, Department of Allergology, Dr von Hauner Children's Hospital University Hospital, LMU Munich, Munich, Germany.,Member of the German Center of Lung Research (DZL), Comprehensive Pneumology Center München (CPC-M), Lübeck, Germany
| | - I Ricklefs
- Department of Pediatric Pneumology and Allergology, University Medical Center Schleswig-Holstein, Lübeck, Germany.,Member of the German Center of Lung Research (DZL), Airway Research Center North (ARCN), Lübeck, Germany
| | - K F Rabe
- Member of the German Center of Lung Research (DZL), Airway Research Center North (ARCN), Lübeck, Germany.,Departement for Internal Medicine I, Pneumology, University Medical Center Schleswig-Holstein, Kiel, Germany
| | - E von Mutius
- Department of Pediatrics, Department of Allergology, Dr von Hauner Children's Hospital University Hospital, LMU Munich, Munich, Germany.,Member of the German Center of Lung Research (DZL), Comprehensive Pneumology Center München (CPC-M), Lübeck, Germany
| | - G Hansen
- Department of Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany.,Member of the German Center of Lung Research (DZL), Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), Lübeck, Germany
| | - I R König
- Member of the German Center of Lung Research (DZL), Airway Research Center North (ARCN), Lübeck, Germany.,Institut für Medizinische Biometrie und Statistik, Universität zu Lübeck, Lübeck, Germany
| | - M V Kopp
- Department of Pediatric Pneumology and Allergology, University Medical Center Schleswig-Holstein, Lübeck, Germany.,Member of the German Center of Lung Research (DZL), Airway Research Center North (ARCN), Lübeck, Germany.,Division of Respiratory Medicine, Department of Pediatrics, Inselspital, University of Bern, Bern, Switzerland
| | | |
Collapse
|
6
|
Brunner-Weinzierl M, Kopp MV. Paradigmenwechsel in der Allergieprävention. Monatsschr Kinderheilkd 2018. [DOI: 10.1007/s00112-018-0512-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
|
7
|
Pfaar O, Bonini S, Cardona V, Demoly P, Jakob T, Jutel M, Kleine-Tebbe J, Klimek L, Klysner S, Kopp MV, Kuna P, Larché M, Muraro A, Schmidt-Weber CB, Shamji MH, Simonsen K, Somoza C, Valovirta E, Zieglmayer P, Zuberbier T, Wahn U. Perspectives in allergen immunotherapy: 2017 and beyond. Allergy 2018; 73 Suppl 104:5-23. [PMID: 29171712 DOI: 10.1111/all.13355] [Citation(s) in RCA: 62] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/08/2017] [Indexed: 01/01/2023]
Abstract
The Future of the Allergists and Specific Immunotherapy (FASIT) workshop provides a regular platform for global experts from academia, allergy clinics, regulatory authorities and industry to review developments in the field of allergen immunotherapy (AIT). The most recent meeting, held in February 2017, had two main themes: advances in AIT and hot topics in AIT from the regulatory point of view. The first theme covered opportunities for personalized AIT, advances in adjuvants and delivery systems, and the development of new molecules and future vaccines for AIT. Key topics in the second part of the meeting were the effects of the enactment of European Directive 2001/83 on the availability of allergens for therapy and diagnosis across the EU, the challenges of conducting Phase 3 studies in the field, the future role of allergen exposure chambers in AIT studies and specific considerations in performing AIT studies in the paediatric population. Finally, the group highlighted the forthcoming EAACI guidelines and their particular importance for the standardization of practice in the treatment of allergies. This review presents a comprehensive insight into those panel discussions and highlights unmet needs and also possible solutions to them for the future.
Collapse
Affiliation(s)
- O. Pfaar
- Department of Otorhinolaryngology; Head and Neck Surgery; Universitätsmedizin Mannheim; Medical Faculty Mannheim; Heidelberg University; Mannheim Germany
- Center for Rhinology and Allergology; Wiesbaden Germany
| | - S. Bonini
- Italian National Research Council; Institute of Translational Pharmacology; Rome, and University of Campania ‘Luigi Vanvitelli’; Naples Italy
- Expert-on Secondment at the European Medicines Agency; London UK
| | - V. Cardona
- Hospital Vall D'Hebron, S. Allergologia, S. Medicina Interna; Barcelona Spain
| | - P. Demoly
- Departement de Pneumologie et Addictologie; Hopital Arnaud de Villeneuve; University Hospital of Montpellier; Montpellier France
| | - T. Jakob
- Department of Dermatology and Allergology; University Medical Center Giessen (UKGM); Justus-Liebig-University Giessen; Giessen Germany
- Allergy Research Group; Department of Dermatology; Medical Center - University Freiburg; Freiburg Germany
| | - M. Jutel
- Department of Clinical Immunology; Wroclaw Medical University; Wroclaw Poland
- All-Med Medical Research Institute; Wroclaw Poland
| | - J. Kleine-Tebbe
- Allergy & Asthma Center Westend; Outpatient Clinic and Clinical Research Center; Berlin Germany
| | - L. Klimek
- Center for Rhinology and Allergology; Wiesbaden Germany
| | - S. Klysner
- Expres ion Biotechnologies Aps; Hørsholm Denmark
| | - M. V. Kopp
- Department of Pediatric Allergy and Pulmonology; University of Luebeck; Luebeck Germany
- Airway Research Center North (ARCN); Member of the Deutsches Zentrum für Lungenforschung (DZL); Luebeck Germany
| | - P. Kuna
- Department of Internal Medicine, Asthma and Allergy; Barlicki University Hospital; Medical University of Lodz; Lodz Poland
| | - M. Larché
- Divisions of Clinical Immunology & Allergy, and Respirology; Department of Medicine and Firestone Institute for Respiratory Health; McMaster University; Hamilton ON Canada
| | - A. Muraro
- Food Allergy Referral Centre; Padua University Hospital; Padua Italy
| | - C. B. Schmidt-Weber
- Center of Allergy and Environment (ZAUM); Member of the German Center for Lung Research (DZL); Technical University of Munich and Helmholtz Center Munich; Munich Germany
| | - M. H. Shamji
- Immunomodulation and Tolerance Group; Allergy and Clinical Immunology; Inflammation Repair and Development; National Heart and Lung Institute; Imperial College; London UK
- MRC & Asthma UK Centre in Allergic Mechanisms of Asthma; London UK
| | | | - C. Somoza
- Biological Products and Biotechnology Division; Medicines for Human Use Department; Agencia Española de Medicamentos y Productos Sanitarios (AEMPS); Madrid Spain
| | - E. Valovirta
- Department of Lung Disease and Clinical Allergology; University of Turku and Terveystalo Allergy Clinic; Turku Finland
| | - P. Zieglmayer
- Allergy Center Vienna West; Vienna Challenge Chamber; Vienna Austria
| | - T. Zuberbier
- Comprehensive Allergy-Centre-Charité; Department of Dermatology and Allergy; Charité - Universitätsmedizin Berlin; Berlin Germany
- Member of Global Allergy and Asthma European Network (GA LEN); GA LEN coordinating Office; Charité - Universitätsmedizin Berlin; Germany
| | - U. Wahn
- Department for Pediatric Pneumology and Immunology; Charité - Universitätsmedizin Berlin; Berlin Germany
| | | |
Collapse
|
8
|
Weckmann M, Schultheiss C, Hollaender A, Bobis I, Rupp J, Kopp MV. Treatment with rhDNase in patients with cystic fibrosis alters in-vitro CHIT-1 activity of isolated leucocytes. Clin Exp Immunol 2016; 185:382-91. [PMID: 27324468 DOI: 10.1111/cei.12827] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/17/2016] [Indexed: 11/28/2022] Open
Abstract
Recent data suggest a possible relationship between cystic fibrosis (CF) pharmacotherapy, Aspergillus fumigatus colonization (AC) and/or allergic bronchopulmonary aspergillosis (ABPA). The aim of this study was to determine if anti-fungal defence mechanisms are influenced by CF pharmacotherapy, i.e. if (1) neutrophils form CF and non-CF donors differ in their ability to produce chitotriosidase (CHIT-1); (2) if incubation of isolated neutrophils with azithromycin, salbutamol, prednisolone or rhDNase might influence the CHIT-1 activity; and (3) if NETosis and neutrophil killing efficiency is influenced by rhDNase. Neutrophils were isolated from the blood of CF patients (n = 19; mean age 26·8 years or healthy, non-CF donors (n = 20; 38·7 years) and stimulated with phorbol-12-myristate-13-acetate (PMA), azithromycin, salbutamol, prednisolone or rhDNase. CHIT-1 enzyme activity was measured with a fluorescent substrate. NETosis was induced by PMA and neutrophil killing efficiency was assessed by a hyphae recovery assay. Neutrophil CHIT-1 activity was comparable in the presence or absence of PMA stimulation in both CF and non-CF donors. PMA stimulation and preincubation with rhDNase increased CHIT-1 activity in culture supernatants from non-CF and CF donors. However, this increase was significant in non-CF donors but not in CF patients (P < 0·05). RhDNase reduced the number of NETs in PMA-stimulated neutrophils and decreased the killing efficiency of leucocytes in our in-vitro model. Azithromycin, salbutamol or prednisolone had no effect on CHIT-1 activity. Stimulation of isolated leucocytes with PMA and treatment with rhDNase interfered with anti-fungal defence mechanisms. However, the impact of our findings for treatment in CF patients needs to be proved in a clinical cohort.
Collapse
Affiliation(s)
- M Weckmann
- Department of Pediatric Allergy and Pulmonology, Clinic of Pediatrics UKSH, University of Luebeck, Luebeck.,Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL)
| | - C Schultheiss
- Department of Pediatric Allergy and Pulmonology, Clinic of Pediatrics UKSH, University of Luebeck, Luebeck.,Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL)
| | - A Hollaender
- Department of Pediatric Allergy and Pulmonology, Clinic of Pediatrics UKSH, University of Luebeck, Luebeck.,Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL)
| | - I Bobis
- Clinic of Internal Medicine, UKSH, University of Kiel, Kiel
| | - J Rupp
- Department of Molecular and Clinical Infectious Diseases, University of Luebeck, Luebeck, Germany
| | - M V Kopp
- Department of Pediatric Allergy and Pulmonology, Clinic of Pediatrics UKSH, University of Luebeck, Luebeck.,Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL)
| |
Collapse
|
9
|
Schmauck-Gómez JS, Menrath I, Kaiser MM, Herz A, Kopp MV. [Children and Adolescents with Asthma Differ in Lung Function Parameters and Exhaled NO from Children and Adolescents with Obesity]. Klin Padiatr 2016; 228:189-94. [PMID: 27362410 DOI: 10.1055/s-0042-102254] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
BACKGROUND The prevalence of asthma and overweight/obesity in children and adolescents is continuously increasing over the last decades. It remains unclear if overweight/obesity raises the risk of developing asthma or if an uncontrolled asthma increases the risk of developing overweight/obesity by restricting physical activity. OBJECTIVES We aimed to elucidate, if children and adolescents with overweight/obesity differ from normal-weight asthmatics in lung functions parameters (FEV1, FEV1/VC, MEF50 and SRtot) and in exhaled nitric oxide (FeNO). METHODS Totally, n=142 children and adolescents aged 6-18 years were included in this study: group 1 comprised n=44 with overweight/obesity defined as a Body-Mass-Index (BMI)>90th percentile; group 2 n=44 with a doctors diagnosed bronchial asthma according to the GINA-guidelines, and group 3 with n=36 pulmonary healthy controls. N=18 children with both asthma and overweight/obesity were excluded from further analysis. We collected data about socio-demographic variables from a standardized questionnaire, bodyplethysmography (FEV1, FEV1/VC, MEF50 and SRtot) and FeNO. RESULTS Normal-weight children and adolescents with asthma had significantly lower FEV1/VC (Tiffenau-Index 90,9±12,8) and MEF50 (84.0% predicted±27.6) than children with overweight/obesity (97,6±12,4 p=0.001 respectively 99.1±20.9 p=0.001) and healthy controls (98±13,5 p=0,003; 96.7±19.3 p=0.011). Normal weight asthmatics had a significantly higher FeNO (38.3 ppb) than children and adolescents with overweight/obesity (14.0 ppb p=0.014). CONCLUSIONS Normal-weight children and adolescents with asthma differ significantly both in their lung function parameters as well as in their exhaled nitric oxide concentration from children and adolescents with overweight/obesity. For clinical practice it is important to note that children and adolescents with overweight/obesity have no signs of an obstructive airway diseases and are as resilient as healthy children and adolescents with regard to their lung function. The possible late-onset of asthma symptoms and lung function changes in children and adolescents with overweight/obesity requires further detailed longitudinal studies.
Collapse
Affiliation(s)
- J S Schmauck-Gómez
- Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL)
| | - I Menrath
- Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL)
| | - M M Kaiser
- Department of Pediatric Surgery, University Hospital of Schleswig-Holstein, Luebeck
| | - A Herz
- Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL)
| | - M V Kopp
- Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL)
| |
Collapse
|
10
|
Schreiber J, Kopp MV, Korn S, Taube C, Buhl R. [Disease modification and duration of omalizumab treatment in patients with severe allergic asthma]. Pneumologie 2014; 68:187-92. [PMID: 24477463 DOI: 10.1055/s-0033-1359242] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
BACKGROUND AND METHODS Omalizumab is a monoclonal anti-IgE-antibody that is used to treat severe allergic asthma. The aim of this review was to evaluate the available evidence in a panel of experts and to provide recommendations on therapy duration with omalizumab. RESULTS A direct or indirect interaction between omalizumab and IgE production seems likely. Pharmacokinetic-pharmakodynamic models suggest that omalizumab modulates IgE production. This hypothesis is currently investigated in clinical studies. In addition, available evidence suggests that omalizumab mitigates different factors of airway remodeling. However, based on the currently available data, no recommendations can be given in regard to reduction of dosage or discontinuation of omalizumab in long term treated patients. CONCLUSIONS Currently, neither dose reductions nor treatment withdrawal can be recommended in patients with severe allergic asthma and long term treatment with omalizumab. Clinical studies addressing these issues are being conducted.
Collapse
Affiliation(s)
- J Schreiber
- Universitätsklinikum der Otto-von-Guericke-Universität Magdeburg, Abteilung für Pneumologie
| | - M V Kopp
- Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Klinik für Kinder- und Jugendmedizin, Pädiatrische Pneumologie und Allergologie, Airway Research Center North (ARCN), Mitglied des Deutschen Zentrums für Lungenforschung (DZL)
| | - S Korn
- Universitätsmedizin der Johannes-Gutenberg-Universität, Mainz, III. Medizinische Klinik und Polyklinik, Schwerpunkt Pneumologie
| | - C Taube
- Leiden University Medical Center, Dept. of Pulmonology
| | - R Buhl
- Universitätsmedizin der Johannes-Gutenberg-Universität, Mainz, III. Medizinische Klinik und Polyklinik, Schwerpunkt Pneumologie
| |
Collapse
|
11
|
Cohn AL, Tabernero J, Maurel J, Nowara E, Sastre J, Chuah BYS, Kopp MV, Sakaeva DD, Mitchell EP, Dubey S, Suzuki S, Hei YJ, Galimi F, McCaffery I, Pan Y, Loberg R, Cottrell S, Choo SP. A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer. Ann Oncol 2013; 24:1777-1785. [PMID: 23510984 DOI: 10.1093/annonc/mdt057] [Citation(s) in RCA: 73] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND Targeted agents presently available for mutant KRAS metastatic colorectal cancer (mCRC) are bevacizumab and aflibercept. We evaluated the efficacy and safety of conatumumab (an agonistic monoclonal antibody against human death receptor 5) and ganitumab (a monoclonal antibody against the type 1 insulin-like growth factor receptor) combined with standard FOLFIRI chemotherapy as a second-line treatment in patients with mutant KRAS mCRC. PATIENTS AND METHODS Patients with mutant KRAS metastatic adenocarcinoma of the colon or rectum refractory to fluoropyrimidine- and oxaliplatin-based chemotherapy were randomized 1 : 1 : 1 to receive intravenous FOLFIRI plus conatumumab 10 mg/kg (Arm A), ganitumab 12 mg/kg (Arm B), or placebo (Arm C) Q2W. The primary end point was progression-free survival (PFS). RESULTS In total, 155 patients were randomized. Median PFS in Arms A, B, and C was 6.5 months (HR, 0.69; P = 0.147), 4.5 months (HR, 1.01; P = 0.998), and 4.6 months, respectively; median overall survival was 12.3 months (HR, 0.89; P = 0.650), 12.4 months (HR, 1.27; P = 0.357), and 12.0 months; and objective response rate was 14%, 8%, and 2%. The most common grade ≥3 adverse events in Arms A/B/C included neutropenia (30%/25%/18%) and diarrhea (18%/2%/10%). CONCLUSIONS Conatumumab, but not ganitumab, plus FOLFIRI was associated with a trend toward improved PFS. Both combinations had acceptable toxicity.
Collapse
Affiliation(s)
- A L Cohn
- Rocky Mountain Cancer Center, Denver, USA.
| | - J Tabernero
- Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona
| | - J Maurel
- Medical Oncology Department, Hospital Clinic de Barcelona, Barcelona, Spain
| | - E Nowara
- Maria Skodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland
| | - J Sastre
- Hospital Clinico San Carlos, Servicio de Oncologíca Medíca, Madrid, and Instituto Carlos III, Spanish Ministry of Science and Innovation, Madrid, Spain
| | - B Y S Chuah
- Department of Internal Medicine, National University Hospital, Singapore, Singapore
| | - M V Kopp
- Samara Regional Oncology Dispensary, Samara
| | - D D Sakaeva
- Clinical Oncology Dispensary of the Republic of Bashkortostan, Ufa, Russia
| | - E P Mitchell
- Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia
| | - S Dubey
- Amgen Inc., South San Francisco
| | | | | | | | | | | | | | | | - S-P Choo
- Medical Oncology, National Cancer Centre Singapore, Singapore
| |
Collapse
|
12
|
Calderon MA, Gerth van Wijk R, Eichler I, Matricardi PM, Varga EM, Kopp MV, Eng P, Niggemann B, Nieto A, Valovirta E, Eigenmann PA, Pajno G, Bufe A, Halken S, Beyer K, Wahn U. Perspectives on allergen-specific immunotherapy in childhood: an EAACI position statement. Pediatr Allergy Immunol 2012; 23:300-6. [PMID: 22594930 DOI: 10.1111/j.1399-3038.2012.01313.x] [Citation(s) in RCA: 86] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
This article is the result of consensus reached by a working group of clinical experts in paediatric allergology as well as representatives from an ethical committee and the European Medicine Agency (EMA). The manuscript covers clinical, scientific, regulatory and ethical perspectives on allergen-specific immunotherapy in childhood. Unmet needs are identified. To fill the gaps and to bridge the different points of view, recommendations are made to researchers, to scientific and patient organizations and to regulators and ethical committees. Working together for the benefit of the community is essential. The European Academy of Allergy and Clinical Immunology (EAACI) serves as the platform of such cooperation.
Collapse
Affiliation(s)
- M A Calderon
- Department of Allergy and Respiratory Medicine, Royal Brompton Hospital, Imperial College, London, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Kopp MV. [The revised guideline on Primary Allergy Prevention]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2012; 55:338-42. [PMID: 22373846 DOI: 10.1007/s00103-011-1431-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
The recommendations of the revised guideline Primary Allergy Prevention published in 2009 are summarized and discussed. The updated guidelines do not further recommend reducing house dust mite allergen exposure as a measure of primary prevention. New suggestions include the avoidance of overweight, and reduction of the exposure to indoor and/or outdoor air pollutants. In line with the current guidelines, there is no scientific evidence that prolonged introduction of solid food is an allergy-preventive measure. Consequently, even children with a family history of atopy can introduce solid foods at the beginning of the 5th month. The recommendations on avoiding environmental tobacco smoke, breast feeding over 4 months, avoiding a mold-promoting indoor climate, vaccination according to current recommendations, and avoidance of furry pets (especially cats) in risk babies have remained unchanged.
Collapse
Affiliation(s)
- M V Kopp
- Klinik für Kinder- und Jugendmedizin, Schwerpunkt Kinderpneumologie, Universität zu Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Deutschland.
| |
Collapse
|
14
|
Bessudo A, Bendell JC, Gabrail N, Kopp MV, Mueller L, Hart LL, Vladimirov VI, Pande AU, Gorbatchevsky I, Eng C. Phase I results of the randomized, placebo controlled, phase I/II study of the novel oral c-MET inhibitor, ARQ 197, irinotecan (CPT-11), and cetuximab (C) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC) who have received front-line systemic therapy. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3582] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
15
|
Koroleva I, Kopp MV, Kasulin AN, Kucheryavyy JA, Byakhov MJ. Late cardiotoxicity in patients with breast cancer after taxane/anthracycline-based neoadjuvant and adjuvant chemotherapy. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e11582] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
16
|
Rensing-Ehl A, Warnatz K, Fuchs S, Schlesier M, Salzer U, Draeger R, Bondzio I, Joos Y, Janda A, Gomes M, Abinun M, Hambleton S, Cant A, Shackley F, Flood T, Waruiru C, Beutel K, Siepermann K, Dueckers G, Niehues T, Wiesel T, Schuster V, Seidel MG, Minkov M, Sirkiä K, Kopp MV, Korhonen M, Schwarz K, Ehl S, Speckmann C. Clinical and immunological overlap between autoimmune lymphoproliferative syndrome and common variable immunodeficiency. Clin Immunol 2010; 137:357-65. [PMID: 20832369 DOI: 10.1016/j.clim.2010.08.008] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2010] [Revised: 08/10/2010] [Accepted: 08/12/2010] [Indexed: 12/27/2022]
Abstract
Autoimmune lymphoproliferative syndrome (ALPS) is mainly caused by defects in the CD95 pathway. Raised CD3+TCRαβ+CD4-CD8- double negative T cells and impaired T cell apoptosis are hallmarks of the disease. In contrast, the B cell compartment has been less well studied. We found an altered distribution of B cell subsets with raised transitional B cells and reduced marginal zone B cells, switched memory B cells and plasma blasts in most of 22 analyzed ALPS patients. Moreover, 5 out of 66 ALPS patients presented with low IgG and susceptibility to infection revealing a significant overlap between ALPS and common variable immunodeficiency (CVID). In patients presenting with lymphoproliferation, cytopenia, hypogammaglobulinemia and impaired B cell differentiation, serum biomarkers were helpful in addition to apoptosis tests for the identification of ALPS patients. Our observations may indicate a role for apoptosis defects in some diseases currently classified as CVID.
Collapse
Affiliation(s)
- A Rensing-Ehl
- Centre of Chronic Immunodeficiency, University Medical Centre, Freiburg, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Grundmann U, Heinzmann A, Schwering L, Urbanek R, Kopp MV. Diagnostic Approach Identifying Hydroxyethyl Starch (HES) Triggering a Severe Anaphylactic Reaction during Anesthesia in a 15-Year-Old Boy. Klin Padiatr 2010; 222:469-70. [DOI: 10.1055/s-0030-1255075] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
18
|
Kopp MV, Koroleva I, Kasulin AN, Kucheryavyy JA, Byakhov MJ. Late pancreatic toxicity in patients with breast cancer after taxane-anthracycline–based neoadjuvant and adjuvant chemotherapy. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e11043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
19
|
Kopp MV, Niggemann B, Forster J. House dust mite allergy: complete removal of the provoking allergen is a primary therapeutic approach. Allergy 2009; 64:1402-3; author reply 1405. [PMID: 19764943 DOI: 10.1111/j.1398-9995.2009.02195.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
20
|
Kopp MV, Hamelmann E, Zielen S, Kamin W, Bergmann KC, Sieder C, Stenglein S, Seyfried S, Wahn U. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy 2009; 39:271-9. [DOI: 10.1111/j.1365-2222.2008.03121.x] [Citation(s) in RCA: 125] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
21
|
Kopp MV, Niggemann B, Forster J. House dust mite allergy: complete removal of the provoking allergen is a primary therapeutic approach. Allergy 2009; 64:187-8; author reply 190. [PMID: 19053989 DOI: 10.1111/j.1398-9995.2008.01882.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
22
|
Walaschek C, Heinzmann A, Weckmann M, Kopp MV. Sulphidoleukotriene release of cord blood basophils in response to allergen stimulation correlates with neither a family history of atopy nor a subsequent development of atopic eczema. Clin Exp Allergy 2008; 38:458-65. [PMID: 18269669 DOI: 10.1111/j.1365-2222.2007.02923.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
OBJECTIVE We tested a possible relationship between sulphidoleukotriene (SLT) release of cord blood (CB) basophils, a family history of atopy (HA) and subsequent development of atopic eczema. Population and methods A cohort of 86 neonates were involved (48.8% males; 46.5% with a positive HA(+)). CB samples were analysed for in vitro SLT release quantified by ELISA, and in a subgroup for basophilic activation (CD 63 expression) by flow cytometry in response to a positive control (anti-IgE-receptor antibody), an allergen-mix (TOP and PTOP), egg white (EW), egg yolk (EY), and the purified allergens beta-lactoglobulin (BLG) and alpha-lactalbumin (ALA). RESULTS Median concentrations of SLT were 124.2 (negative), 3871.5 (positive), 123.9 (TOP), 128.5 (PTOP), 113.1 (EW), 108.4 (EY), 125.2 (BLG) and 122.3 (ALA) pg/mL. Groups of HA(+) and HA(-) show no difference in all analysed allergens. An allergen-specific SLT release (defined as SLT>125 pg/mL above individual baseline and a stimulation index >2) was detected in 98% (positive control), 5% (TOP), 7% (BLG), 3% (ALA) and 2% (EW and EY), respectively. After a median observation period of 18 months, n=7 out of 70 children developed an atopic eczema, but we observed no association between CB SLT release (positive response to at least one tested allergen). CONCLUSION Allergen-specific SLT release is detectable in 15.5% of healthy neonates, irrespective of their family history of atopy. However, early allergen-specific SLT release is not predictive for the development of atopy.
Collapse
Affiliation(s)
- C Walaschek
- University Children's Hospital, Freiburg, Germany
| | | | | | | |
Collapse
|
23
|
Kopp MV, Goldstein M, Dietschek A, Sofke J, Heinzmann A, Urbanek R. Lactobacillus GG has in vitro effects on enhanced interleukin-10 and interferon-gamma release of mononuclear cells but no in vivo effects in supplemented mothers and their neonates. Clin Exp Allergy 2007; 38:602-10. [PMID: 18167121 DOI: 10.1111/j.1365-2222.2007.02911.x] [Citation(s) in RCA: 56] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND The value of probiotics for primary prevention is controversial. Moreover, only little is known about the underlying immunological mechanisms of action. Therefore, we assessed the proliferative response and cytokine release in cultures of isolated mononuclear cells from pregnant women and their neonates supplemented with Lactobacillus GG (LGG) or placebo. METHODS In a double-blind, placebo-controlled prospective trial, pregnant women with at least one first-degree relative or a partner with an atopic disease were randomly assigned to receive either the probiotic LGG (ATCC 53103; 5 x 10(9) colony-forming units LGG twice daily) or placebo 4-6 weeks before expected delivery, followed by a post-natal period of 6 months. Cord blood mononuclear cells (CBMC) and peripheral blood mononuclear cells (PBMC) of the corresponding mother were isolated from cord blood and peripheral blood (n=68). The proliferative response of CBMC and PBMC was expressed as the stimulation index (SI), which was calculated according to the ratio between the mean counts per minute (c.p.m.) values measured in the wells with stimulated cells and the mean c.p.m. values measured in the wells with unstimulated cells. Additionally, the cytokines IFN-gamma, IL-10 and IL-13 in the cell culture supernatants were measured using the ELISA technique. RESULTS No difference was observed between the LGG-supplemented group and the placebo group in terms of the proliferative capacity of maternal or neonatal cord blood cells in response to IL-2, beta-lactoglobulin or LGG. In vitro stimulation with LGG resulted in significantly enhanced release of IL-10 and IFN-gamma, compared with cytokine release in unstimulated controls. However, this phenomenon was observed in supernatants of maternal and neonatal MC in both groups, independent of prior supplementation with LGG. CONCLUSION LGG has in vitro effects on enhanced IL-10 and IFN-gamma release of mononuclear cells. However, supplementation with LGG during pregnancy did not alter the proliferative capacity or cytokine pattern in their recipients.
Collapse
Affiliation(s)
- M V Kopp
- University Children's Hospital, Freiburg, Germany.
| | | | | | | | | | | |
Collapse
|
24
|
Ionova TI, Novik AA, Kishtovich AV, Kaliadina SA, Koroleva IA, Kopp MV, Fedorenko DA, Rikov IV, Gorodokin GI. Fatigue and grades of quality of life (QoL) impairment in advanced cancer. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.8207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- T. I. Ionova
- National Medcl Surg Ctr, Moscow, Russian Federation; National Pirogov Medcl Surg Ctr, Moskow, Russian Federation; Regional Oncology Hosp, Samara, Russian Federation; New Jersey Ctr for QoL and Health Outcome Res., New Jersey, NJ
| | - A. A. Novik
- National Medcl Surg Ctr, Moscow, Russian Federation; National Pirogov Medcl Surg Ctr, Moskow, Russian Federation; Regional Oncology Hosp, Samara, Russian Federation; New Jersey Ctr for QoL and Health Outcome Res., New Jersey, NJ
| | - A. V. Kishtovich
- National Medcl Surg Ctr, Moscow, Russian Federation; National Pirogov Medcl Surg Ctr, Moskow, Russian Federation; Regional Oncology Hosp, Samara, Russian Federation; New Jersey Ctr for QoL and Health Outcome Res., New Jersey, NJ
| | - S. A. Kaliadina
- National Medcl Surg Ctr, Moscow, Russian Federation; National Pirogov Medcl Surg Ctr, Moskow, Russian Federation; Regional Oncology Hosp, Samara, Russian Federation; New Jersey Ctr for QoL and Health Outcome Res., New Jersey, NJ
| | - I. A. Koroleva
- National Medcl Surg Ctr, Moscow, Russian Federation; National Pirogov Medcl Surg Ctr, Moskow, Russian Federation; Regional Oncology Hosp, Samara, Russian Federation; New Jersey Ctr for QoL and Health Outcome Res., New Jersey, NJ
| | - M. V. Kopp
- National Medcl Surg Ctr, Moscow, Russian Federation; National Pirogov Medcl Surg Ctr, Moskow, Russian Federation; Regional Oncology Hosp, Samara, Russian Federation; New Jersey Ctr for QoL and Health Outcome Res., New Jersey, NJ
| | - D. A. Fedorenko
- National Medcl Surg Ctr, Moscow, Russian Federation; National Pirogov Medcl Surg Ctr, Moskow, Russian Federation; Regional Oncology Hosp, Samara, Russian Federation; New Jersey Ctr for QoL and Health Outcome Res., New Jersey, NJ
| | - I. V. Rikov
- National Medcl Surg Ctr, Moscow, Russian Federation; National Pirogov Medcl Surg Ctr, Moskow, Russian Federation; Regional Oncology Hosp, Samara, Russian Federation; New Jersey Ctr for QoL and Health Outcome Res., New Jersey, NJ
| | - G. I. Gorodokin
- National Medcl Surg Ctr, Moscow, Russian Federation; National Pirogov Medcl Surg Ctr, Moskow, Russian Federation; Regional Oncology Hosp, Samara, Russian Federation; New Jersey Ctr for QoL and Health Outcome Res., New Jersey, NJ
| |
Collapse
|
25
|
Rolinck-Werninghaus C, Wolf H, Liebke C, Baars JC, Lange J, Kopp MV, Hammermann J, Leupold W, Bartels P, Gruebl A, Bauer CP, Schnitker J, Wahn U, Niggemann B. A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen. Allergy 2004; 59:1285-93. [PMID: 15507097 DOI: 10.1111/j.1398-9995.2004.00627.x] [Citation(s) in RCA: 87] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
BACKGROUND Especially in childhood, sublingual immunotherapy (SLIT) could offer advantages over subcutaneous therapy. However, limited data on its efficacy is available. METHODS In four German centres 97 children (age 3-14 years) with allergic rhinoconjunctivitis to grass pollen were enrolled in a prospective, double-blind trial comparing SLIT (Pangramin SLIT; ALK-SCHERAX, 0.5 microg major allergens, three times per week, 32 months) with placebo. Primary endpoint was a multiple symptom-medication score for changes in seasonal diary entries between the first and third year of the study (SLIT n=39; placebo n=38). RESULTS The multiple symptom-medication score was significantly reduced by SLIT to 77.3% of the placebo group (P=0.0498). The subsequent analysis of the single endpoints did not reveal significant differences for symptom scores in favour of SLIT (85.1% of placebo group; P=0.22). However, the medication score improved significantly (67.1% of placebo group; P=0.0025). Furthermore, secondary endpoints assessing in vivo immune responses did not differ significantly between the groups. However, retrospective analysis showed some inhomogeneity for clinical and in vitro parameters at the beginning of the study. Allergic side effects with possible relation to the study drug were reported in both groups (SLIT 49%, placebo 27%, P=0.026). CONCLUSION Our study indicates that SLIT had a positive effect on the reduction of a multiple symptom-medication score, mainly by significantly reducing rescue medication use, but had no significant effect on symptoms alone in children with rhinoconjunctivitis to grass pollen compared with a placebo.
Collapse
|
26
|
Kopp MV, Kühr J. Anti-IgE-Antikörper (Omalizumab). Monatsschr Kinderheilkd 2004. [DOI: 10.1007/s00112-004-0955-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
27
|
Lange J, Ngoumou G, Berkenheide S, Moseler M, Mattes J, Kuehr J, Kopp MV. High interleukin-13 production by phytohaemagglutinin- and Der p 1-stimulated cord blood mononuclear cells is associated with the subsequent development of atopic dermatitis at the age of 3 years. Clin Exp Allergy 2004; 33:1537-43. [PMID: 14616866 DOI: 10.1046/j.1365-2222.2003.01789.x] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
OBJECTIVE The aim of our study was to conduct a prospective investigation into the potential association of cord blood proliferative response and cytokine production in response to various stimuli on the development of atopic dermatitis (AD) at the age of 3 years. METHODS Cord blood mononuclear cells (CBMC) from 40 healthy term neonates were isolated. The proliferative response of CBMC stimulated with IL-2, betalactoglobulin (BLG) and house dust mite allergen (Der p 1) was assessed by liquid scintillation counting and the stimulation index (SI) was calculated. The cytokines interleukin (IL-)13, interferon (IFN-)gamma, IL-10 and IL-18 in the cell culture supernatants in response to phytohaemagglutinin (PHA), Der p 1 and BLG were measured using the ELISA technique. After 3 years, symptoms of AD were obtained with a questionnaire completed by the parents. RESULTS We observed significantly higher IL-13 levels in response to PHA in children who subsequently developed symptoms of AD (S: median, 291 pg/mL) compared with asymptomatic children (No-S: 149 pg/mL; P=0.021, Wilcoxon test). Similarly, in response to Der p 1 significantly higher IL-13 levels were observed in symptomatic children (S: 168.6; No-S: 61.6 pg/mL; P=0.0084). In response to BLG, IL-13 levels were 287.2 (S) and 123.6 pg/mL (No-S; P=0.19). No significant differences were found when comparing the IFN-gamma levels in CBMC cultures stimulated with PHA (S: 10.2; No-S: 17.6 IU/L; P=0.78), Der p 1 (S: 307.6; No-S: 616.2 IU/L; P=0.2) or BLG (S: 18; No-S: 28.5 IU/L; P=0.83; Fig. 2). The IL-18 and IL-10 levels and the stimulation index in response to IL-2, BLG and Der p 1 showed no significant difference between children who subsequently developed symptoms of AD and asymptomatic children. CONCLUSION Our data suggest that enhanced IL-13 levels at birth are associated with the subsequent development of atopic symptoms at the age of 3 years.
Collapse
Affiliation(s)
- J Lange
- University Children's Hospital, Freiburg, Germany
| | | | | | | | | | | | | |
Collapse
|
28
|
Kopp MV, Zehle C, Pichler J, Szépfalusi Z, Moseler M, Deichmann K, Forster J, Kuehr J. Allergen-specific T cell reactivity in cord blood: the influence of maternal cytokine production. Clin Exp Allergy 2001; 31:1536-43. [PMID: 11678853 DOI: 10.1046/j.1365-2222.2001.01198.x] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
BACKGROUND Successful pregnancy is dependent upon T helper (Th)2-type-dominated immunological responsiveness in gestation-associated compartments. OBJECTIVE In our study we observed the influence of the maternal Th2-associated cytokine pattern on the naive fetal T cell phenotype and asked if circulating Th2 cytokines of atopic mothers affects the Th1/Th2 differentiation of the fetus. METHODS Cord blood mononuclear cells (CBMC) and peripheral blood mononuclear cells (PBMC) of the corresponding mothers were isolated. The proliferative response of CBMC and PBMC to Betalactoglobulin (BLG) was assessed by liquid scintillation counting. The cytokines interferon (IFN)-gamma, and interleukin (IL)-5, IL-10 and IL-13 in the cell culture supernatants were measured using the ELISA technique. We then defined two subgroups based on maternal levels of specific IgE against aeroallergens: sensitized mothers (MA(+)) and their neonates (NMA(+)) (n = 18) and non-sensitized mothers (MA(-)) and their neonates (NMA(-)) (n = 29). RESULTS Nearly all mothers (98%) and neonates (92%) had a positive proliferation response after stimulation with BLG (mean stimulation index (10-90 percentile): neonates: 7 (2-15); mothers 14 (5-29)). In supernatants of BLG-stimulated cell cultures, sensitized mothers showed a significantly lower IFN-gamma concentration in comparison to non-sensitized mothers (MA(+) = 25; MA(-) = 123 IU/L; P < 0,05), whereas the neonates did not differ significantly (NMA(+) = 306; NMA(-) = 224 IU/L; n. s.). Nor was any difference found in the IL-13 concentration between the two groups of sensitized and non-sensitized mothers (MA(+) = 48; MA(-) = 125 pg/mL; n. s.). CBMC of neonates with a sensitized mother showed significantly higher IL-13 concentrations in response to BLG than neonates of non-sensitized mothers (NMA(+) = 1442, NMA(-) 738 pg/mL; P < 0.05). The IL-5 and IL-10 concentrations did not differ significantly within the neonatal and the maternal subgroups. CONCLUSIONS Our data suggests that maternal sensitization to allergens is associated with the reduced maternal production of the Th2 antagonist IFN-gamma and elevated production of the Th2 cytokine IL-13 in the offspring.
Collapse
Affiliation(s)
- M V Kopp
- University Children's Hospital, Freiburg, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Vougioukas VI, Berlis A, Kopp MV, Korinthenberg R, Spreer J, van Velthoven V. Neurosurgical interventions in children with Maroteaux-Lamy syndrome. Case report and review of the literature. Pediatr Neurosurg 2001; 35:35-8. [PMID: 11490189 DOI: 10.1159/000050383] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
This paper reports the case of a 14-year-old child with Maroteaux-Lamy syndrome (mucopolysaccharidosis type 6) who was treated consecutively for compressive damage of the optic nerves, hydrocephalus communicans and progressive spastic tetraparesis within 2 years. The clinical course of the patient is presented and the pathophysiologic mechanisms of disease progression in patients with Maroteaux-Lamy syndrome are discussed and reviewed.
Collapse
Affiliation(s)
- V I Vougioukas
- Department of Neurosurgery, University of Freiburg, Germany.
| | | | | | | | | | | |
Collapse
|
30
|
Kopp MV, Bohnet W, Frischer T, Ulmer C, Studnicka M, Ihorst G, Gardner C, Forster J, Urbanek R, Kuehr J. Effects of ambient ozone on lung function in children over a two-summer period. Eur Respir J 2000; 16:893-900. [PMID: 11153589 DOI: 10.1183/09031936.00.16589300] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
There is a general consensus that short term exposure to ozone (O3) causes a decrease in lung function parameters such as forced vital capacity (FVC) and forced expiratory volume in one second (FEV1). The objective of this study was to assess the reproducibility of lung function decrements after ambient O3 exposure over a two-summer period. The authors studied 797 children with a mean age of 8.2 yrs (95% confidence interval: 6.9-9.5) from the second and third grades of ten elementary schools in Austria and southwestern Germany. At the outset the various study locations were stratified into three groups with low (L), medium (M) and high (H) O3 exposure (range of mean O3 concentration in the locations April-October 1994: 24-30 (L); 33-38 (M); 44-52 (H) parts per billion (ppb)). Four lung function tests were performed on each child between March 1994 and November 1995. The increases in FVC and FEV1 recorded from one test period to the next were expressed as mL x day(-1). A significantly lower FVC and FEV1 increase was observed in children exposed to high ambient O3 concentration during the summer season. (FVC in summer 1994: 0.83 (L); 0.56 (M); 0.55 (H) mL x day(-1); p=0.004; and summer 1995: 0.80 (L); 0.63 (M); 0.56 (H) mL x day(-1); p=0.011; FEV1 in summer 1994: 0.48 (L); 0.34 (M); 0.18 (H) mL x day(-1); p=0.004 and summer 1995: 0.68 (L); 0.45 (M); 0.41 (H) mL x day(-1), p=0.006). There was no significant difference in FVC or FEV1 increase between the groups during the winter period. Adjusting for sex, age, height and passive smoke exposure, linear regression revealed a statistically significant negative association of average ambient O3 concentration with the FVC and FEV1 increase in both summers. During the winter period no association of O3 with FVC or FEV1 was observed. In conclusion, in two consecutive summer periods the authors found reproducible lung function decrements in children exposed to high levels of ambient ozone. Reoccurrence of ozone associated lung function deficits might increase the likelihood of persisting effects on the childrens' airways.
Collapse
Affiliation(s)
- M V Kopp
- University Childrens Hospital, Freiburg, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Kopp MV, Pichler J, Halmerbauer G, Kuehr J, Frischer T, Urbanek R, Szépfalusi Z. Culture conditions for the detection of allergen-specific T-cell reactivity in cord blood: influence of cell number. Pediatr Allergy Immunol 2000; 11:4-11. [PMID: 10768730 DOI: 10.1034/j.1399-3038.2000.00053.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Raised T-cell proliferation of cord blood mononuclear cells (CBMC) in response to various ingestant and inhalant allergens has been reported in newborns, suggesting a prenatal allergen contact. In general, for in vitro proliferation assays a concentration of 50 x 10(3) or 100 x 10(3) cells/well are used. The aim of this study was to analyze whether cell concentration influences T-cell reactivity in cord blood cells and to study differences of T-cell reactivity triggered by inhalant and ingestant allergens. CBMC from 51 neonates (34 females: 22 with and 29 without a family history of allergy, i.e. FH+ or FH-) were incubated with interleukin-2 (IL-2), beta-lactoglobulin (beta-LG), ovalbumin (OVA), house dust mite allergen Dermatophagoides pteronyssinus (Der p 1), and timothy grass allergen Phleum pratense (Ph1 p 1) for 7 days. The cell concentration ranged from 6.25 x 10(3) to 100 x 10(3) cells/well. Proliferation was assessed by incorporation of [3H]-thymidine and was expressed as counts per minute (c.p.m.). In unstimulated cells, a decreasing cell concentration paralleled a steep drop of background activity. In response to IL-2, a decreasing cell concentration led to a slow decrease of c.p.m. The corresponding mean stimulation indices (SI) were 9, 32, 77, 47, and 21 for 100 x 10(3), 50 x 10(3), 25 x 10(3), 12.5 x 10(3), and 6.25 x 10(3) cells/well, respectively. In addition, the highest number of positive proliferative responses to specific allergens were obscured at lower cell concentrations. For beta-LG, the maximal number of positive responses were obtained between 25 x 10(3) (n = 44) and 12.5 x 10(3) (n = 46) cells/well, for OVA at 25 x 10(3) (n = 3) cells/well, for Der p 1 at 50 x 10(3) (n = 5) cells/well, and for Ph1 p 1 between 25 x 10(3) and 12.5 x 10(3) (n = 5) cells/well. Positive proliferation in at least one of the tested assays was observed in 100% of samples in response to beta-LG, in 22% in response to Ph1 p 1, and in 14% in response to OVA and Der p 1. T-cell reactivity did not differ between samples of newborns with or without a family history of atopy. Therefore, sensitivity of T-cell proliferation measurement is highly influenced by background proliferation of unstimulated cells. Hence, proliferation assays with lower cell numbers unmask T-cell reactivity in response to ingestant and inhalant allergens. We suggest the use of concentrations of 12.5 x 10(3)-50 x 10(3) cells/well in proliferation experiments.
Collapse
Affiliation(s)
- M V Kopp
- University Children's Hospital, Vienna, Austria.
| | | | | | | | | | | | | |
Collapse
|
32
|
Kopp MV, Ulmer C, Ihorst G, Seydewitz HH, Frischer T, Forster J, Kuehr J. Upper airway inflammation in children exposed to ambient ozone and potential signs of adaptation. Eur Respir J 1999; 14:854-61. [PMID: 10573233 DOI: 10.1034/j.1399-3003.1999.14d22.x] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
In order to investigate nasal inflammation and subsequent adaptation after ambient ozone exposure, nasal lavage (NL) fluid was collected from 170 schoolchildren on 11 occasions (time points) between March and October. Eosinophil cationic protein (ECP), albumin and leukocytes were quantified as markers of nasal inflammation. The highest half-hour outdoor O3 concentration for each individual on the day prior to the NL was used as a measure of exposure (O3indiv). To avoid confounding with exposure to common environmental allergens, the study population was restricted to children without sensitization to inhalant allergens. In the initial period of increased O3 levels in May (time point 4), with a median O3indiv of 135 microg x m(-3) (5th-95th percentile 100-184 microg x m(-3)), the highest medians of all 11 leukocyte and ECP measurements were observed. The highest O3indiv were observed in June at time point 7 (O3indiv 173 microg x m(-3), 5th-95th percentile 120-203 microg x m(-3)). Cross-sectional analysis of all 11 time points revealed no significant association of O3indiv on the one hand and ECP, albumin and leukocyte levels on the other. A multivariable model estimated using generalized estimating equations showed a statistically significant association of O3indiv and leukocytes and ECP as the dependent variable, when time points 1-4 were analysed (p<0.05). In the same model, this association diminished continuously when time points 5-11 were added stepwise, in spite of high O3 exposure. Not even a tendency towards an O3 effect could be recognized when time points 1-8 were considered. The results indicate: 1) acute inflammation of the nasal mucosa after the first increase in ambient ozone levels, with 2) a significant dose-dependent increase in leukocyte and eosinophil cationic protein levels, and 3) possible adaptation of the nasal mucosa in spite of constant high levels of ozone exposure in children during the summer season.
Collapse
Affiliation(s)
- M V Kopp
- University Children's Hospital, Freiburg, Germany
| | | | | | | | | | | | | |
Collapse
|